Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.

Purpose: To develop recommendations for adjuvant therapy for patients with resected stage II colon cancer.

Methods: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.

Results: Twenty-one observational studies and six randomized controlled trials met the systematic review inclusion criteria.

Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.

Purpose: To develop recommendations for duration of adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin for patients with completely resected stage III colon cancer based on the results of trials of 3 months compared with 6 months of treatment.

Methods: ASCO convened an Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel.